Predict your next investment

Corporation
INDUSTRIAL | Manufacturing / Laboratory & Research Equipment Manufacturing
novasep.com

See what CB Insights has to offer

Portfolio Exits

3

Partners & Customers

10

About Novasep

Novasep is a supplier of manufacturing solutions for life sciences molecules and fine chemicals. The company's offering includes process development services, purification equipment and turnkey processes, contract manufacturing services, and complex active molecules to serve pharmaceutical, biopharmaceutical, fine chemical, food, and functional ingredients as well as fermentation and chemical commodities industries.

Novasep Headquarter Location

39, rue Saint-Jean de Dieu

Lyon, 69007,

France

+33 437 282 030

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Novasep Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Novasep Rank

Novasep Portfolio Exits

3 Portfolio Exits

Novasep has 3 portfolio exits. Their latest portfolio exit was Novasep - Viral-vector Manufacturing Business on January 15, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/15/2021

Divestiture

$991

1

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

1/15/2021

00/00/0000

00/00/0000

Exit

Divestiture

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

10

10

Novasep Acquisitions

1 Acquisition

Novasep acquired 1 company. Their latest acquisition was TangenX Technology on December 22, 2006.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/22/2006

Corporate Majority

Corporate Majority

1

Date

12/22/2006

Investment Stage

Corporate Majority

Companies

Valuation

Total Funding

Note

Corporate Majority

Sources

1

Novasep Partners & Customers

10 Partners and customers

Novasep has 10 strategic partners and customers. Novasep recently partnered with Exelixis on July 7, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

7/6/2021

Client

Exelixis

United States

Novasep, Exelixis Ink ADC Manufacturing Agreement

Novasep , a supplier of services and technologies for the life sciences industry , has signed a manufacturing services agreement with Exelixis , an oncology-focused biotech , for the cGMP clinical production of XB002 , a next-generation tissue factor-targeting antibody-drug conjugate for oncology applications .

4

11/12/2020

Client

AstraZeneca

United Kingdom

Press releases - Covid-19 vaccine candidate: Novasep signs a Master Supply and Development Agreement with AstraZeneca

This new contract follows the initial agreement signed between AstraZeneca and Novasep Belgium on June 14th in the context of the Inclusive Alliance for Vaccines , whose members are France , Germany , Italy and the Netherlands .

1

11/2/2020

Client

Handl Therapeutics

Belgium

BRIEF—Novasep and Handl sign gene therapy product development and manufacturing deal

Belgian companies Novasep and Handl have signed an agreement for the development and manufacturing of an adeno associated virus - based gene therapy drug candidate for the treatment of neurodegenerative diseases .

2

10/26/2020

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

7/8/2020

Client

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

7/6/2021

11/12/2020

11/2/2020

10/26/2020

7/8/2020

Type

Client

Client

Client

Partner

Client

Business Partner

Exelixis

AstraZeneca

Handl Therapeutics

Country

United States

United Kingdom

Belgium

Subscribe to see more

Subscribe to see more

News Snippet

Novasep, Exelixis Ink ADC Manufacturing Agreement

Novasep , a supplier of services and technologies for the life sciences industry , has signed a manufacturing services agreement with Exelixis , an oncology-focused biotech , for the cGMP clinical production of XB002 , a next-generation tissue factor-targeting antibody-drug conjugate for oncology applications .

Press releases - Covid-19 vaccine candidate: Novasep signs a Master Supply and Development Agreement with AstraZeneca

This new contract follows the initial agreement signed between AstraZeneca and Novasep Belgium on June 14th in the context of the Inclusive Alliance for Vaccines , whose members are France , Germany , Italy and the Netherlands .

BRIEF—Novasep and Handl sign gene therapy product development and manufacturing deal

Belgian companies Novasep and Handl have signed an agreement for the development and manufacturing of an adeno associated virus - based gene therapy drug candidate for the treatment of neurodegenerative diseases .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

4

1

2

10

10

Novasep Team

10 Team Members

Novasep has 10 team members, including current Chief Executive Officer, President, Michel Spagnol.

Name

Work History

Title

Status

Michel Spagnol

Chief Executive Officer, President

Current

Jean Bléhaut

President

Current

Damien Brichant

President

Current

Philippe Stoll

President

Current

Olivier Chéron

Chief Financial Officer

Current

Name

Michel Spagnol

Jean Bléhaut

Damien Brichant

Philippe Stoll

Olivier Chéron

Work History

Title

Chief Executive Officer, President

President

President

President

Chief Financial Officer

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.